The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
it still shows as AIM market. would you tell me where did you get the news?
@ RideEasy
You are absolutely right.
IF ANYBODY THINK THIS IS A SMALL CONTRACT YOU NEED TO READ THIS STATMENT FEW TIMES AND IF YOU DONT UNDERSTAND IT READ AGAIN AND AGAIN UNTIL YOU DO.
Next steps
Following the successful Phase II results, further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in MGC EU GMP facilities as IMP under a new brand name. In addition, different indications related to inflammation and cytokine storm will be considered as future development goals and include a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, flu, and chemotherapy patients.
The Company is in a strong position to respond to a significant potential increase in the demand for ArtemiC™ in the immediate future as a supplement, and in the future as part of a Phase III study where the Company would look to develop ArtemiC™ as a pharmaceutical product and future development as an Investigational Medicinal Product (IMP).
Regulatory approvals to commence the Phase III Clinical Trial will be progressed with Anvisa (Brazilian medical Authority), EU Novel Food authority, and submissions are expected to be made in the first quarter of 2021. The Company plans to develop and commence a Phase III Clinical Trial in the first half of 2021. The Phase III Clinical trial is anticipated to be an international multicentre study with up to 250 patients and expand its research to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment. These indications are related to cytokines storm as autoimmune diseases (rheumatoid arthritis, lupus), flu, chemotherapy patients and IBD could benefit from the mechanism of action ArtemiC™, demonstrated in preclinical and clinical trials.
Upon completion of a successful Phase III Clinical Trial, the Company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.
Successful results of Phase III will lead for a pre-IND meeting with FDA in order to initiate the registration process for ArtemiC™ as an IMP.
Please do not listen to people with little knowledge. Do your own research and decide for yourself. as I mentioned before we will see a day £1 entry would be a bargain for lots of people. This will happen before you know it.
All the beast
@pawnsacrifice
Thanks, mate
At the moment they are able to make 10,000 units of ArtemiC as a supplement per week in Slovenia but soon as they passed a Phase III clinical they are able to make 10,000 units ArtemiC as a medicine per day.
Please listen to this interview for more info
https://youtu.be/04dKV8oDIqU
Next steps
Following the successful Phase II results, further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in MGC EU GMP facilities as IMP under a new brand name. In addition, different indications related to inflammation and cytokine storm, will be considered as future development goals and include a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, flu and chemotherapy patients.
The Company is in a strong position to respond to a significant potential increase in the demand for ArtemiC™ in the immediate future as a supplement, and in the future as part of a Phase III study where the Company would look to develop ArtemiC™ as a pharmaceutical product and future development as an Investigational Medicinal Product (IMP).
Regulatory approvals to commence the Phase III Clinical Trial will be progressed with Anvisa (Brazilian medical Authority), EU Novel Food authority and submissions are expected to be made in first quarter of 2021. The Company plans to develop and commence a Phase III Clinical Trial in the first half of 2021. The Phase III Clinical trial is anticipated to be an international multicentre study with up to 250 patients and expand its research to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment. These indications are related to cytokines storm as autoimmune diseases (rheumatoid arthritis, lupus), flu, chemotherapy patients and IBD could benefit from the mechanism of action ArtemiC™, demonstrated in preclinical and clinical trials.
Upon completion of a successful Phase III Clinical Trial the Company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.
Successful results of Phase III will lead for a pre-IND meeting with FDA in order to initiate the registration process for ArtemiC™ as an IMP.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The results we have seen from ArtemiC™ to date provide a transformational opportunity for the Company. The safety and efficacy demonstrated on COVID-19 patients has now opened the opportunity for a whole range of other indications related to cytokine storm. The Company will now look to progress the immediate opportunities for ArtemiC™ while continuing to pursue further clinical developments.”
Next steps
Following the successful Phase II results, further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in MGC EU GMP facilities as IMP under a new brand name. In addition, different indications related to inflammation and cytokine storm, will be considered as future development goals and include a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, flu and chemotherapy patients.
The Company is in a strong position to respond to a significant potential increase in the demand for ArtemiC™ in the immediate future as a supplement, and in the future as part of a Phase III study where the Company would look to develop ArtemiC™ as a pharmaceutical product and future development as an Investigational Medicinal Product (IMP).
Regulatory approvals to commence the Phase III Clinical Trial will be progressed with Anvisa (Brazilian medical Authority), EU Novel Food authority and submissions are expected to be made in first quarter of 2021. The Company plans to develop and commence a Phase III Clinical Trial in the first half of 2021. The Phase III Clinical trial is anticipated to be an international multicentre study with up to 250 patients and expand its research to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment. These indications are related to cytokines storm as autoimmune diseases (rheumatoid arthritis, lupus), flu, chemotherapy patients and IBD could benefit from the mechanism of action ArtemiC™, demonstrated in preclinical and clinical trials.
Upon completion of a successful Phase III Clinical Trial the Company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.
Successful results of Phase III will lead for a pre-IND meeting with FDA in order to initiate the registration process for ArtemiC™ as an IMP.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: “The results we have seen from ArtemiC™ to date provide a transformational opportunity for the Company. The safety and efficacy demonstrated on COVID-19 patients has now opened the opportunity for a whole range of other indications related to cytokine storm. The Company will now look to progress the immediate opportunities for ArtemiC™ while continuing to pursue further clinical developments.”
Multinationals like Altria Group Inc (NYSE: MO) have already made indirect forays into the market, and you would be sitting pretty if you own shares in GW Pharmaceuticals (NASDAQ: GWPH), after Irish biopharmaceutical company Jazz Pharmaceuticals successfully pitched a $7.2bn (£5.25bn) offer (at a sizeable premium) for the Cambridge-based developer of cannabinoid-based medicines.
News of the deal would also have played well with shareholders in newly listed MGC Pharmaceuticals (MXC), another developer of cannabis-derived medicines. MGC’s London listing was significantly oversubscribed, while shares in Kanabo, a producer of vaporised marijana pods and inhalors, saw its shares double on its recent debut. But investors would do well to avoid getting caught up in the hype over the widespread commercialisation of the cannabis industry. Liberalisation could give way to an erratic and unpredictable period for participants. Any progress on the legislative front would almost certainly reduce barriers to entry, which could rapidly give way to an overcrowded field. As things stand, there are stringent controls in place for growers. Logic dictates that any relaxation will draw in capital and encourage start-ups across the industry.
IF ANYBODY THINK THIS IS A SMALL CONTRACT YOU NEED TO READ THIS STATMENT FEW TIMES AND IF YOU DONT UNDERSTAND IT READ AGAIN AND AGAIN UNTIL YOU DO.
Next steps
Following the successful Phase II results, further development for ArtemiC™ will include immediate evaluation of a Phase III clinical study on COVID-19 and flu patients, and production in MGC EU GMP facilities as IMP under a new brand name. In addition, different indications related to inflammation and cytokine storm will be considered as future development goals and include a wide range of diseases related to cytokine storm such as autoimmune diseases, inflammatory GI diseases, flu, and chemotherapy patients.
The Company is in a strong position to respond to a significant potential increase in the demand for ArtemiC™ in the immediate future as a supplement, and in the future as part of a Phase III study where the Company would look to develop ArtemiC™ as a pharmaceutical product and future development as an Investigational Medicinal Product (IMP).
Regulatory approvals to commence the Phase III Clinical Trial will be progressed with Anvisa (Brazilian medical Authority), EU Novel Food authority, and submissions are expected to be made in the first quarter of 2021. The Company plans to develop and commence a Phase III Clinical Trial in the first half of 2021. The Phase III Clinical trial is anticipated to be an international multicentre study with up to 250 patients and expand its research to encompass a wide range of inflammatory indications for the use of ArtemiC™ as a treatment. These indications are related to cytokines storm as autoimmune diseases (rheumatoid arthritis, lupus), flu, chemotherapy patients and IBD could benefit from the mechanism of action ArtemiC™, demonstrated in preclinical and clinical trials.
Upon completion of a successful Phase III Clinical Trial, the Company will seek registration of ArtemiC™ and commence production and sale as a supplement, through its existing production facilities and distribution networks.
Successful results of Phase III will lead for a pre-IND meeting with FDA in order to initiate the registration process for ArtemiC™ as an IMP.
Please do not listen to people with little knowledge. Do your own research and decide for yourself. as I mentioned before we will see a day £1 entry would be a bargain for lots of people. This will happen before you know it.
All the beast
sorry guys I was double-checked that news it wasn't right.
?
I think we need to compare MGC with GWP.
GWP Development Pipeline:
CBDV (GWP42006)
1. This is a homologue of cannabidiol currently being developed for the treatment of epilepsy and autism spectrum disorders. It has a very slightly different chemical structure to the original molecule but has been shown to posses similar properties. It is also a non-psychoactive cannabinoid. It is currently in the initial stages of development, but has so far shown promising results. ( Epilepsy / Autism Spectrum Disorders both are in phase 2)
2. In addition, we have a number of other products at various stages in the development pipeline. These include GWP42003 IV for Neonatal Hypoxic-Ischemic Encephalopathy, GWP42002/GWP42003 for Glioblastoma, and GWP42003 for Schizophrenia. ( Neonatal Hypoxic-Ischemic Encephalopathy / Glioblastoma / Schizophrenia )
*********************
MGC Development Pipeline:
1. CANNEPIL® – DESIGNED FOR TREATMENT OF REFRACTORY EPILEPSY
Phase IIb Clinical Trial at Schneider Hospital in Israel on the safety and efficacy of CannEpil® as an add on treatment in children and adolescents with refractory epilepsy
A controlled trial with the Swinburne University of Technology, Melbourne to assess the effect of CannEpil® on driving performance
2. COGNICANN® - DESIGNED FOR TREATMENT OF DEMENTIA AND ALZHEIMER’S DISEASE
Phase II Clinical Trial with the University of Notre Dame in Perth, WA to evaluate the potential behavioral benefits CogniCann®may have on patients with dementia and Alzheimer’s disease
3. ARTEMIC – DESIGNED FOR TREATMENT OF COVID-19
Phase II Clinical Trial on ArtemiC is designed to target viral infections with inflammatory complications, and currently, the safety and efficacy are being evaluated on COVID-19 infected patients. Trials are currently being undertaken at Nazareth Hospital EMMS and Hillel Yaffe Hospital in Israel, and Mahatma Gandhi Mission’s Medical College & Hospital, India
**********************
So if we look at these pipelines for these 2 companies, we can see they are not the same as other cannabis companies such as Canabo, Aphria, Aurora which they making CBD oil for vape.
I'm not a god but I believe £1 entry would be a bargain for lots of people in near future.
is up to you where you want to invest your money.
@Bushmaster
Thanks mate
I read the RNS a few times is f@@king huge. congregation to anybody who is in already
Kanabo will be down %30 TO %50 tomorrow
and people going to invest the money in vape company lol
I feel bad for dose guys they sold them share today before market close
Master Supply & Distribution agreement signed with Swiss
PharmaCan AG for exclusive worldwide1 distribution of
ArtemiCTM Rescue
Key Highlights:
• Minimum three (3) year exclusive worldwide1
supply and distribution agreement signed with
leading European nutraceuticals producer and distributor, Swiss PharmaCan AG, for the
distribution of ArtemiCTM Rescue as a food supplement
• This agreement follows the completion of a successful phase II double-blind, placebo-
controlled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary
and secondary endpoints
• Agreement includes minimum wholesale order quantity to MGC Pharma of 40,000 units of
ArtemiCTM Rescue per quarter
• Initial wholesale order of 10,000 units received by MGC Pharma, which has a total retail
market value of US$850,000 for Swiss PharmaCan AG
• MGC Pharma to also produce and provide daily dosage immune support supplement
ArtemiC™ Support, for daily use.
• Swiss PharmaCan AG to exclusively distribute ArtemiCTM Rescue and ArtemiC™ Support
worldwide1
, with specific focus on countries currently reporting high numbers of COVID-19
• The Company has sufficient manufacturing capacity at its production facility in Slovenia to
produce commercial scale batches of ArtemiCTM Rescue and ArtemiC™ Support for
distribution by Swiss PharmaCan AG
• Additionally, Swiss PharmaCan AG has already secured agreement with Relay Medical Corp.
(CSE: RELA) and Glow LifeTech Ltd. for exclusive North American and Caribbean sales and
distribution rights for ArtemiCTM Rescue and ArtemiC™ Prevention
• Swiss PharmaCan AG has also secured ONASIS Holdings Corp. (OTC: ONSS) as Master
Distributor of ArtemiC™ Rescue and ArtemiC™ Prevention through their channels in USA and
Central America.
We can call this pre RNS
Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC(TM) Following Successful COVID-19 Phase II Clinical Trial
Toronto, Ontario--(Newsfile Corp. - February 16, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company"), a technology developer and innovator, and Glow LifeTech Ltd. ("Glow"), a private company in which Relay holds a significant equity interest, are pleased to report that Glow has executed an agreement with Swiss Pharmacan AG ("the agreement") for exclusive North American and Carribean sales and distribution rights for ArtemiC™ , a natural health product based on Glow's MyCell™ Technology ("MyCell") which recently reported successful results from a COVID-19 Phase II clinical trial (see Relay's release dated Jan 14, 2021).
Under the terms of the agreement, signed on February 16, 2021, Glow has exclusive rights to market, sell and distribute ArtemiC™ in Canada, U.S., Mexico and all Carribean countries as a food supplement. ArtemiC™ is a clinically tested food supplement (nutraceutical, dietary supplement, natural health product) containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses Glow's MyCell™ delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC™ was a collaborative development effort with Glow's strategic partner, Swiss PharmaCan AG and MGC Pharma ("MGC"), and will be manufactured by MGC Pharma under EU-GMP.
"This is a significant new product opportunity for Glow and our shareholders, as ArtemiC™ shows promising results that it may improve the clinical recovery of COVID-19 patients," said Rob Carducci, Chief Commercial Officer, Glow LifeTech Ltd. "We are extremely pleased that our MyCell™ Technology is helping to power a natural, safe and effective product that can be made widely accessible during these challenging times."
Recently, MGC announced the results of a Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC™ statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group[1]. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC™ required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing done by MGC on toxicity and mechanism of action.
https://www.newsfilecorp.com/release/74643/Relay-Medical-Reports-Glow-LifeTech-Secures-Exclusive-North-American-Rights-to-ArtemiCTM-Following-Successful-COVID19-Phase-II-Clinical-Trial
I think we will fly with or without RNS. but I'm not a god